HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Enters India’s Consumer Market With Universal Medicare Buy

This article was originally published in The Tan Sheet

Executive Summary

Sanofi’s search for high-growth consumer brands in India led to the firm’s Aug. 24 acquisition of Universal Medicare Pvt. Ltd.’s nutraceutical business.

You may also be interested in...



Danone Buys Wockhardt's Nutrition Brands That Abbott Won Then Lost

After several months of discussions, debt-laden Indian drug maker Wockhardt Ltd. managed to sell its growing nutritional business to French food giant Group Danone for a reported $354 million

Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 2 of 2)

Arjun Oberoi, Sanofi-Aventis' vice president for business development Asia Pacific, mirrors his company's leadership ambitions in the Asian markets. Open to calculated risks and high on energy, Oberoi has played a leading role in clinching a few important deals for Sanofi such as last year's acquisition of China OTC play BMP Sunstone and its joint venture with Minsheng Pharmaceutical Group ('Sanofi Expands Consumer Health Reach With New Joint Venture In China,' PharmAsia News, Feb. 1, 2010).

Reckitt Continues Asian Push With $724M Paras Purchase

Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel